SHARP trial (simvastatin plus ezetimibe in CKD) results published in the Lancet. PDF Print
Lancet: Interpretation - Reduction of LDL cholesterol with simvastatin 20 mg plus ezetimibe 10 mg daily safely reduced the incidence of major atherosclerotic events in a wide range of patients with advanced chronic kidney disease.

...

 
Share |
Copyright © 2025 Global Dialysis. All Rights Reserved.